Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist.

The extremely low permeability of the blood-brain barrier (BBB) poses the greatest impediment in the treatment of central nervous system (CNS) diseases. Recent work indicated that BBB permeability can be up-regulated by activating A2A adenosine receptor (AR), which temporarily increases intercellular spaces between the brain capillary endothelial cells. However, due to transient circulation lifetime of adenosine-based agonists, their capability to enhance brain delivery of drugs, especially macromolecular drugs, is limited. In this work, a series of nanoagonists (NAs) were developed by labeling different copies of A2A AR activating ligands on dendrimers. In vitro transendothelial electrical resistance measurements demonstrated that the NAs increased permeability of the endothelial cell monolayer by compromising the tightness of tight junctions, the key structure that restricts the entry of blood-borne molecules into the brain. In vivo imaging studies indicated the remarkably up-regulated brain uptake of a macromolecular model drug (45 kDa) after intravenous injection of NAs. Autoradiographic imaging showed that the BBB opening time-window can be tuned in a range of 0.5-2.0 h by the NAs labeled with different numbers of AR-activating ligands. By choosing a suitable NA, it is possible to maximize brain drug delivery and minimize the uncontrollable BBB leakage by matching the BBB opening time-window with the pharmacokinetics of a therapeutic agent. The NA-mediated brain drug delivery strategy holds promise for the treatment of CNS diseases with improved therapeutic efficiency and reduced side-effects.

[1]  A. Mendonça,et al.  Adenosine receptors in the nervous system: pathophysiological implications , 2002, Progress in Neurobiology.

[2]  Mu-Yi Hua,et al.  Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. , 2010, Radiology.

[3]  Thomas Wisniewski,et al.  Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging , 2011, NeuroImage.

[4]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[5]  L. Kobzik,et al.  Lung macrophage uptake of unopsonized environmental particulates. Role of scavenger-type receptors. , 1995, Journal of immunology.

[6]  K. Jacobson,et al.  Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. , 2009, Bioconjugate chemistry.

[7]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[8]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[9]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[10]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[11]  William A Goddard,et al.  pKa calculations of aliphatic amines, diamines, and aminoamides via density functional theory with a Poisson-Boltzmann continuum solvent model. , 2007, The journal of physical chemistry. A.

[12]  Z. Bhujwalla,et al.  Facile synthesis of 1-(acetic acid)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraaza-cyclododecane: a reactive precursor chelating agent. , 2009, Tetrahedron letters.

[13]  K. Jacobson,et al.  Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. , 2008, Bioconjugate chemistry.

[14]  G. Ravizzini,et al.  Dendrimers in medical nanotechnology , 2009, IEEE Engineering in Medicine and Biology Magazine.

[15]  R. Busto,et al.  Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats , 1996, Brain Research.

[16]  Xihui Gao,et al.  Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier. , 2014, Small.

[17]  M. Chopp,et al.  MRI of Blood–Brain Barrier Permeability in Cerebral Ischemia , 2012, Translational Stroke Research.

[18]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[19]  Shailendra Joshi,et al.  Enhanced Disruption of the Blood Brain Barrier by Intracarotid Mannitol Injection During Transient Cerebral Hypoperfusion in Rabbits , 2007, Journal of neurosurgical anesthesiology.

[20]  R. Egleton,et al.  Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier , 2001, Trends in Neurosciences.

[21]  M. Mcpartlin,et al.  Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions , 1995 .

[22]  L. Kiessling,et al.  Synthetic Multivalent Ligands as Probes of Signal Transduction , 2006 .

[23]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[24]  Stephen P. H. Alexander,et al.  [3H]ZM241385—an antagonist radioligand for adenosine A2A receptors in rat brain , 2001 .

[25]  Manuel de Lera Ruiz,et al.  Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.

[26]  Yao-Sheng Tung,et al.  Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. , 2010, Ultrasound in medicine & biology.

[27]  E. Frenkel,et al.  Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. , 1983, Cancer research.

[28]  A. Gubitz,et al.  Tissue distribution of adenosine receptor mRNAs in the rat , 1996, British journal of pharmacology.

[29]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[30]  Kullervo Hynynen,et al.  Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.

[31]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Imad Najm,et al.  Seizure‐Promoting Effect of Blood–Brain Barrier Disruption , 2007, Epilepsia.

[33]  J. Minna,et al.  Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. , 1985, Cancer research.

[34]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[35]  M. Bynoe,et al.  Adenosine Receptor Signaling Modulates Permeability of the Blood–Brain Barrier , 2011, The Journal of Neuroscience.

[36]  S. Rapoport.  Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications , 2000, Cellular and Molecular Neurobiology.

[37]  R. Groszmann,et al.  Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition , 2009, Hepatology.

[38]  Colin M. Wilson,et al.  Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors , 2009, Journal of Translational Medicine.

[39]  J. Kaye,et al.  Blood–brain barrier impairment in Alzheimer disease , 2007, Neurology.

[40]  P. Turner.  The Blood-Brain Barrier in Health and Disease , 1987 .

[41]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[42]  Xiaofen Li,et al.  N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists. , 2007, Bioorganic & medicinal chemistry letters.

[43]  A. Hubbard,et al.  Transcytosis: crossing cellular barriers. , 2003, Physiological reviews.

[44]  B. Barres,et al.  Pericytes are required for blood–brain barrier integrity during embryogenesis , 2010, Nature.

[45]  H. Luhmann,et al.  Volatile Anesthetics Influence Blood-Brain Barrier Integrity by Modulation of Tight Junction Protein Expression in Traumatic Brain Injury , 2012, PloS one.

[46]  Lu Wang,et al.  Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. , 2012, ACS nano.

[47]  H. Lei,et al.  Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. , 2011, Chemical communications.

[48]  S. Cazaubon,et al.  The blood-brain barrier in brain homeostasis and neurological diseases. , 2009, Biochimica et biophysica acta.

[49]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[50]  J. Benoit,et al.  Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. , 2009, Biomaterials.

[51]  R. Bendayan,et al.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.

[52]  Jacobson,et al.  Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. , 2010, Bioconjugate chemistry.

[53]  木下 学.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption , 2007 .

[54]  Bengt R. Johansson,et al.  Pericytes regulate the blood–brain barrier , 2010, Nature.

[55]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.